2019 is drawing to a close, and what a year it has been for pharma and biotech...
The cell and gene therapies industry focused on automation, scaling up and lowering CoGs of newly-approved products such as those in CAR-T. Organizations across the oligonucleotides, peptides, mRNA and genome editing sectors explored methods of collaborating to strengthen the production of medicine.
Over in antibody engineering, we highlighted changes to the market since monoclonal antibodies burst onto the scene, and the industry’s increasing thirst for technological innovations. Meanwhile, the young microbiome therapeutics sector looked to areas of further development.
We gathered the full list of the ten most read posts of 2019 into an interactive flip-book - simply click the image below (or HERE).
